Pelin G. Ersan

755 total citations
9 papers, 262 citations indexed

About

Pelin G. Ersan is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Pelin G. Ersan has authored 9 papers receiving a total of 262 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Pelin G. Ersan's work include Cancer Cells and Metastasis (3 papers), RNA modifications and cancer (2 papers) and Cancer, Hypoxia, and Metabolism (2 papers). Pelin G. Ersan is often cited by papers focused on Cancer Cells and Metastasis (3 papers), RNA modifications and cancer (2 papers) and Cancer, Hypoxia, and Metabolism (2 papers). Pelin G. Ersan collaborates with scholars based in Türkiye, United States and Germany. Pelin G. Ersan's co-authors include Özgür Şahin, Özge Saatci, Umar Raza, Ünal Metin Tokat, Yasser Riazalhosseini, Suhail A. Ansari, Erol Eyüpoğlu, Caglar Cekic, Tolga Can and Hasan Oğul and has published in prestigious journals such as Nature Communications, Cancer Research and Clinical Cancer Research.

In The Last Decade

Pelin G. Ersan

8 papers receiving 261 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pelin G. Ersan Türkiye	7	182	97	76	36	29	9	262
Tanya Schild United States	7	189 1.0×	146 1.5×	99 1.3×	39 1.1×	35 1.2×	9	313
Daniel Otero-Albiol Spain	8	215 1.2×	101 1.0×	150 2.0×	33 0.9×	23 0.8×	13	361
Yutaro Otsuka Japan	10	203 1.1×	78 0.8×	132 1.7×	42 1.2×	33 1.1×	10	328
Sau Wai Hung United States	9	257 1.4×	166 1.7×	199 2.6×	29 0.8×	21 0.7×	9	395
Yitao Wang China	10	230 1.3×	95 1.0×	89 1.2×	26 0.7×	46 1.6×	11	330
Riona Tully Ireland	2	180 1.0×	97 1.0×	141 1.9×	37 1.0×	39 1.3×	2	309
Shu-Heng Jiang China	3	114 0.6×	59 0.6×	61 0.8×	70 1.9×	25 0.9×	3	214
Oksana Mashadova United States	4	175 1.0×	105 1.1×	86 1.1×	16 0.4×	12 0.4×	5	252
Kathrin Weidele Germany	6	117 0.6×	73 0.8×	75 1.0×	22 0.6×	11 0.4×	8	198
Chunxu Yang China	10	254 1.4×	104 1.1×	68 0.9×	25 0.7×	33 1.1×	15	356

Countries citing papers authored by Pelin G. Ersan

Since Specialization

Citations

This map shows the geographic impact of Pelin G. Ersan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pelin G. Ersan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pelin G. Ersan more than expected).

Fields of papers citing papers by Pelin G. Ersan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pelin G. Ersan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pelin G. Ersan. The network helps show where Pelin G. Ersan may publish in the future.

Co-authorship network of co-authors of Pelin G. Ersan

This figure shows the co-authorship network connecting the top 25 collaborators of Pelin G. Ersan. A scholar is included among the top collaborators of Pelin G. Ersan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pelin G. Ersan. Pelin G. Ersan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Saatci, Özge, Metin Çetįn, Ünal Metin Tokat, et al.. (2023). Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer. Nature Communications. 14(1). 6997–6997. 6 indexed citations

Tokat, Ünal Metin, Özge Saatci, Pelin G. Ersan, et al.. (2022). Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer. Breast Cancer Research and Treatment. 193(2). 331–348. 39 indexed citations

Wang, Lin, Luz M. Londono, Özge Saatci, et al.. (2021). Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors. Cancer Research. 81(12). 3319–3332. 29 indexed citations

Ersan, Pelin G., et al.. (2021). TLR ligand loaded exosome mediated immunotherapy of established mammary Tumor in mice. Immunology Letters. 239. 32–41. 33 indexed citations

Siddiqui, Aarif, Paradesi Naidu Gollavilli, Annemarie Schwab, et al.. (2019). Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers. Cell Death and Differentiation. 26(11). 2223–2236. 34 indexed citations

Karayel, Özge, Ayşe Nur Polat, Özge Saatci, et al.. (2019). Systems-level Analysis Reveals Multiple Modulators of Epithelial-mesenchymal Transition and Identifies DNAJB4 and CD81 as Novel Metastasis Inducers in Breast Cancer. Molecular & Cellular Proteomics. 18(9). 1756–1771. 33 indexed citations

Ansari, Suhail A., Umar Raza, Pelin G. Ersan, et al.. (2018). Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer. Clinical Cancer Research. 24(8). 1987–2001. 44 indexed citations

Cohen, Noam, Pelin G. Ersan, Rachel Eyre, et al.. (2017). EACR-MRS conference on Seed and Soil: In Vivo Models of Metastasis. Clinical & Experimental Metastasis. 34(8). 449–456.

Raza, Umar, Özge Saatci, Stefan Uhlmann, et al.. (2016). The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer. Oncotarget. 7(31). 49859–49877. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact